​

Gilead Sciences (GILD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GILD Stock Forecast

Gilead Sciences (GILD) stock forecast, based on 24 Wall Street analysts, predicts a 12-month average price target of $88.88, with a high of $105.00 and a low of $71.00. This represents a -9.34% decline from the last price of $98.04.

$60 $69 $78 $87 $96 $105 High: $105 Avg: $88.88 Low: $71 Last Closed Price: $98.04

GILD Stock Rating

Gilead Sciences stock's rating consensus is Buy, based on 24 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (66.67%), 8 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 24 8 16 0 Strong Sell Sell Hold Buy Strong Buy

GILD Price Target Upside V Benchmarks

TypeNameUpside
StockGilead Sciences-9.34%
SectorHealthcare Stocks 23.08%
IndustryDrug Manufacturers - General Stocks18.59%

Price Target Trends

1M3M12M
# Anlaysts1220
Avg Price Target$83.00$94.00$84.45
Last Closing Price$98.04$98.04$98.04
Upside/Downside-15.34%-4.12%-13.86%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 2541211--27
Jan, 2541312--29
Dec, 2451413--32
Nov, 2471415--36
Oct, 24711161-35
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 07, 2025Brian AbrahamsRBC Capital$83.00$90.63-8.42%-15.34%
Nov 07, 2024Joseph CatanzaroPiper Sandler$105.00$90.0916.55%7.10%
Oct 21, 2024Evan David SeigermanBMO Capital$94.00$86.119.16%-4.12%
Oct 21, 2024Andrew BerensLeerink Partners$96.00$86.7210.70%-2.08%
Oct 18, 2024Terence FlynnMorgan Stanley$84.00$87.07-3.53%-14.32%
Sep 23, 2024Michael YeeJefferies$95.00$83.7613.42%-3.10%
Sep 12, 2024Salveen RichterGoldman Sachs$71.00$82.85-14.30%-27.58%
Sep 12, 2024Terence FlynnMorgan Stanley$79.00$82.63-4.39%-19.42%
Sep 11, 2024Joseph CatanzaroPiper Sandler$95.00$79.9318.85%-3.10%
Aug 14, 2024Asthika GoonewardeneTruist Financial$83.00$74.1411.95%-15.34%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 10, 2025Morgan StanleyReduceOverweightupgrade
Jan 07, 2025RBC CapitalSector PerformSector Performhold
Nov 13, 2024CitigroupBuyinitialise
Oct 21, 2024BernsteinOutperformOutperformhold
Oct 21, 2024RBC CapitalUnderperformUnderperformhold
Oct 21, 2024Leerink PartnersOutperformupgrade
Oct 18, 2024Cowen & Co.BuyBuyhold
Oct 17, 2024BMO CapitalOutperformOutperformhold
Oct 17, 2024BernsteinOutperforminitialise
Oct 07, 2024Wells FargoSector PerformOverweightupgrade

Financial Forecast

EPS Forecast

$0 $2 $4 $6 $8 $10 $11 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.07$4.96$3.66$4.54-----
Avg Forecast$6.95$8.20$7.10$6.75$4.38$7.59$7.95$8.47$9.07
High Forecast$6.74$7.96$6.84$6.58$3.87$6.40$5.77$5.94$8.66
Low Forecast$7.22$8.53$7.42$7.05$4.72$8.42$9.84$10.05$9.61
Surprise %-98.99%-39.51%-48.45%-32.74%-----

Revenue Forecast

$24B $26B $28B $30B $32B $34B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.69B$27.30B$27.28B$27.12B-----
Avg Forecast$24.37B$26.67B$26.53B$27.10B$28.32B$28.49B$29.34B$30.74B$32.22B
High Forecast$23.80B$26.05B$25.78B$26.91B$28.10B$27.87B$29.31B$30.63B$31.10B
Low Forecast$25.12B$27.48B$27.44B$27.28B$28.60B$29.85B$29.36B$30.85B$33.68B
Surprise %1.30%2.38%2.84%0.06%-----

Net Income Forecast

$-5B $-1B $3B $7B $11B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$89.00M$6.22B$4.59B$5.67B-----
Avg Forecast$-826.75M$5.09B$3.23B$5.67B$5.40B$9.33B$7.55B$8.20B$11.41B
High Forecast$-2.31B$4.07B$2.58B$4.53B$4.87B$8.06B$7.26B$7.47B$10.90B
Low Forecast$656.68M$6.10B$3.88B$6.80B$5.94B$10.60B$12.37B$12.64B$12.09B
Surprise %-110.77%22.36%42.16%------

GILD Forecast FAQ

Is Gilead Sciences stock a buy?

Gilead Sciences stock has a consensus rating of Buy, based on 24 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 8 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Gilead Sciences is a favorable investment for most analysts.

What is Gilead Sciences's price target?

Gilead Sciences's price target, set by 24 Wall Street analysts, averages $88.88 over the next 12 months. The price target range spans from $71 at the low end to $105 at the high end, suggesting a potential -9.34% change from the previous closing price of $98.04.

How does Gilead Sciences stock forecast compare to its benchmarks?

Gilead Sciences's stock forecast shows a -9.34% downside, underperforming the average forecast for the healthcare stocks sector (23.08%) and underperforming the drug manufacturers - general stocks industry (18.59%).

What is the breakdown of analyst ratings for Gilead Sciences over the past three months?

  • February 2025: 14.81% Strong Buy, 44.44% Buy, 40.74% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 13.79% Strong Buy, 44.83% Buy, 41.38% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 15.62% Strong Buy, 43.75% Buy, 40.62% Hold, 0% Sell, 0% Strong Sell.

What is Gilead Sciences’s EPS forecast?

Gilead Sciences's average annual EPS forecast for its fiscal year ending in December is $4.38 for 2024, a -3.52% decrease from the reported $4.54 in 2023. The prediction for 2025 is $7.59, $7.95 for 2026, $8.47 for 2027, and $9.07 for 2028.

What is Gilead Sciences’s revenue forecast?

Gilead Sciences's average annual revenue forecast for its fiscal year ending in December is $28.32B for 2024, a 4.43% increase from the reported $27.12B in 2023. The forecast for 2025 is $28.49B, $29.34B for 2026, $30.74B for 2027, and $32.22B for 2028.

What is Gilead Sciences’s net income forecast?

For its fiscal year ending in December, Gilead Sciences's average annual net income forecast is $5.4B for 2024, reflecting a -4.61% decrease from the reported $5.66B in 2023. The projection for 2025 is $9.33B, $7.55B for 2026, $8.2B for 2027, and $11.41B for 2028.